

## Investor Class PHPIX

Annual Shareholder Report – July 31, 2024

This Annual shareholder report contains important information about the Pharmaceuticals UltraSector ProFund Investor Class (the "Fund") for the period of August 1, 2023 to July 31, 2024. You can find additional information about the Fund at [www.profund.com/shareholder-reports](http://www.profund.com/shareholder-reports). You can also request this information by contacting us at 888-776-3637.

## What were the Fund's costs for the last year?

(based on a hypothetical \$10,000 investment)


Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Investor Class	\$174	1.78%

## How did the Fund perform last year?

**Pharmaceuticals UltraSector ProFund** (the "Fund") seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) of the daily performance of the S&P Pharmaceuticals Select Industry Index (the "Index"). The Fund invests in financial instruments that ProFund Advisors believes, in combination, should produce daily returns consistent with the Fund's investment objective. For the year ended July 31, 2024, the Fund had an average daily statistical correlation of over 0.99 to one and one-half times the daily performance of the Index. For the same period, the Index had a total return of 0.42% and a volatility of 16.68%. Pharmaceutical stocks delivered muted performance in an equity rally that favored technology stocks. Primary factors affecting Fund performance include the total return of the securities and derivatives held by the Fund, the performance of the reference assets to which the derivatives are linked, financing rates paid or earned, expenses, transaction costs, the volatility of the Fund's Index, the impact of compounding, and other miscellaneous factors.

## Cumulative performance: August 1, 2014 through July 31, 2024

Total Return Based on \$10,000 Investment



The chart above represents historical performance of a hypothetical investment of \$10,000 in the Fund over the past ten years (or since inception if shorter). Performance data quoted represents past performance and does not guarantee future results. Returns shown are total returns, which assume the reinvestment of dividends and capital gains. The table and graph presented above do not reflect the deduction of taxes a shareholder would pay on Fund distributions or the redemption of fund shares.

### Fund Statistics

Net Assets	\$3,006,205
Number of Holdings*	49
Investment Advisory Fees	\$5,604
Portfolio Turnover	207%

\* No. of Holdings excludes derivatives and collateral for securities loaned.

### Average Annual Total Returns

	1 Year	5 years	10 years
Fund NAV	(4.98)%	5.31%	4.00%
S&P Total Market Index	21.10	14.13	12.51
S&P Pharmaceuticals Select Industry Index	0.42	3.76	1.09
S&P 500® Index	22.15	15.00	13.15

### Market Exposure

Investment Type	% of Net Assets
Equity Securities	83%
Swap Agreements	67%
<b>Total</b>	<b>150%</b>

"Market Exposure" includes the value of total investments (including the contract value of any derivatives) and excludes any instruments used for cash management or collateral for securities loaned.

### S&P Pharmaceuticals Select Industry Index - Composition

Pharmaceuticals	100%
-----------------	------

### Largest Equity Holdings

Company	% of Net Assets
Axsome Therapeutics, Inc.	3.5%
Viartis, Inc.	3.5%
Intra-Cellular Therapies, Inc.	3.5%
Bristol-Myers Squibb Co.	3.4%
Pfizer, Inc.	3.3%

## Material Fund Changes

The Fund has evaluated the need for additional disclosures through the date this report was issued. Based on this evaluation, there are no additional disclosures that would have a material impact on the Fund's financial statements.

## Changes In Or Disagreements With Accountants

During the fiscal year ended July 31, 2024, there were no changes in the Fund's Independent Registered Public Accounting Firm.

"Standard & Poor's<sup>®</sup>", "S&P<sup>®</sup>" and "S&P Pharmaceuticals Select Industry Index" are trademarks of Standard & Poor's Financial Services LLC ("S&P") and have been licensed for use by ProFunds. This Fund is not sponsored, licensed, sold or promoted by Standard & Poor's and Standard & Poor's makes no representation regarding the advisability of investing in ProFunds.

## Pharmaceuticals UltraSector ProFund

Investor Class PHPIX  
Annual Shareholder Report – July 31, 2024

Additional information about the Fund including the Financial Statements, Prospectus and Statement of Additional Information is available: On the Fund's website, <https://www.profunds.com/shareholder-reports>, or upon request, by calling 888-776-3637.

